Avantor® Receives 2025 Edison Patent Award for Sustainable Viral Inactivation Technology

Rhea-AI Summary

Avantor (NYSE: AVTR) and Amgen received a 2025 Edison Patent Award from the Research & Development Council of New Jersey for a biodegradable detergent that enables safer, more sustainable viral inactivation in biomanufacturing.

The jointly developed detergent is described as delivering effective viral inactivation while maintaining protein integrity and increasing process yield, providing an environmentally responsible alternative for producing monoclonal antibodies, vaccines, and gene therapies. Work was co-developed at Avantor's Bridgewater Innovation Center and highlights industry collaboration and New Jersey's role in scientific innovation.

News Market Reaction

+2.95%

1 alert

+2.95% News Effect

On the day this news was published, AVTR gained 2.95%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Research & Development Council of New Jersey honors Avantor for developing a biodegradable detergent solution that advances safe, sustainable biomanufacturing

RADNOR, Pa., Nov. 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the Company, in partnership with Amgen, received a 2025 Edison Patent Award from the Research & Development Council of New Jersey. The recognition was for their pioneering development of a biodegradable detergent that enables safer, more sustainable viral inactivation in biomanufacturing.

Co-developed by Avantor and Amgen, Avantor's detergent delivers effective viral inactivation while maintaining protein integrity and increasing process yield. This jointly developed technology addresses a critical industry challenge by providing a compliant, high-performing, and environmentally responsible alternative for producing monoclonal antibodies, vaccines, and gene therapies.

"We are honored to be recognized by the R&D Council of New Jersey for this achievement," said Benoit Gourdier, Executive Vice President, Bioscience Production, Avantor. "Our collaboration demonstrates how strategic partnerships can drive scientific innovation and environmental responsibility to advance biomanufacturing. By developing safer, more effective detergents, Avantor is supporting our customers in producing vital therapies responsibly and with less impact on the environment."

Co-developed at Avantor's Bridgewater Innovation Center, this work strengthens Avantor's leadership in sustainable bioprocessing while showcasing the power of industry collaboration. The partnership also reinforces New Jersey's position as a global hub for scientific innovation and sustainable technology.

Read more about how Avantor developed J.T.Baker Viral Inactivation here.

About Avantor
Avantor^® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Avantor Media Contact
Eric Van Zanten
Head of External Communications
610-529-6219
Eric.Vanzanten@avantorsciences.com 

Avantor Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
908-329-7281
Allison.Hosak@avantorsciences.com

View original content:https://www.prnewswire.com/news-releases/avantor-receives-2025-edison-patent-award-for-sustainable-viral-inactivation-technology-302624676.html

SOURCE Avantor and Financial News

FAQ

What did Avantor (AVTR) win on November 25, 2025?

Avantor and Amgen received the 2025 Edison Patent Award for a biodegradable viral inactivation detergent.

What is the purpose of Avantor's biodegradable detergent developed with Amgen?

It enables safer, sustainable viral inactivation while maintaining protein integrity and increasing process yield for biologics.

Where was Avantor's viral inactivation technology developed?

The technology was co-developed at Avantor's Bridgewater Innovation Center.

How does the detergent affect biomanufacturing of monoclonal antibodies and vaccines?

The detergent provides a compliant, high-performing, environmentally responsible alternative for producing monoclonal antibodies, vaccines, and gene therapies.

Does the announcement mention financial or revenue impact for AVTR?

No— the announcement describes the award and technology benefits but does not provide financial or revenue figures.

Why is this award significant for New Jersey and investors tracking AVTR?

The award highlights industry collaboration and Avantor's role in sustainable bioprocessing, reinforcing New Jersey as a hub for scientific innovation.